Literature DB >> 21623862

A mechanism for the action of the compound DA-6034 on NF-κB pathway activation in Helicobacter pylori-infected gastric epithelial cells.

S H Ko1, D Y Yoo1, Y-J Kim1, S M Choi1, K K Kang1, H Kim1, N Kim1, J S Kim1, J M Kim1.   

Abstract

DA-6034 is a synthetic derivative of eupatilin, a flavonoid with anti-inflammatory effects. The aim of this study was to investigate the effects of DA-6034 on the interactions between IκB kinase (IKK) and heat shock protein 90 (Hsp90), and activation of the nuclear factor-kappaB (NF-κB) signalling pathway in human gastric epithelial cells infected with Helicobacter pylori. MKN-45 gastric epithelial cell line was treated with DA-6034 and H. pylori. DA-6034 significantly inhibited NF-κB activation and upregulated the expressions of interleukin-8 (IL-8) and monocyte chemoattractant protein-1 in MKN-45 cells infected with H. pylori. However, DA-6034 did not influence activator protein-1 DNA binding activity in H. pylori-infected gastric epithelial cells. Pretreatment with DA-6034 attenuated the H. pylori-induced increase in IKK activity, and Hsp90 was associated with IKK-α and IKK-γ in MKN-45 cells. Treatment with DA-6034 dissociated the Hsp90 and IKK-γ complex in H. pylori-infected cells, leading to the inhibition of IL-8 expression. These results suggest that the eupatilin derivative 7-carboxymethyloxy-3',4',5-trimethoxy flavone has anti-inflammatory activity in gastric epithelial cells infected with H. pylori through the promotion of the dissociation of the IKK-γ-Hsp90 complex and suppression of NF-κB signalling.
© 2011 The Authors. Scandinavian Journal of Immunology © 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21623862     DOI: 10.1111/j.1365-3083.2011.02577.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  6 in total

1.  Pharmacokinetics, safety and tolerability of DA-6034, an anti-inflammatory agent, after single and multiple oral administrations in healthy volunteers.

Authors:  Jieon Lee; Kwang-Hee Shin; Jung-Ryul Kim; Kyoung Soo Lim; In-Jin Jang; Jae-Yong Chung
Journal:  Clin Drug Investig       Date:  2014-01       Impact factor: 2.859

Review 2.  Helicobacter pylori and interleukin-8 in gastric cancer.

Authors:  Ko Eun Lee; Pham Ngoc Khoi; Yong Xia; Jung Sun Park; Young Eun Joo; Kyung Keun Kim; Seok Yong Choi; Young Do Jung
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 3.  Attempts to enhance the eradication rate of Helicobacter pylori infection.

Authors:  Chang Seok Bang; Gwang Ho Baik
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

4.  DA-6034 Induces [Ca(2+)]i Increase in Epithelial Cells.

Authors:  Yu-Mi Yang; Soonhong Park; Hyewon Ji; Tae-Im Kim; Eung Kweon Kim; Kyung Koo Kang; Dong Min Shin
Journal:  Korean J Physiol Pharmacol       Date:  2014-04-03       Impact factor: 2.016

Review 5.  Helicobacter pylori Virulence Factors-Mechanisms of Bacterial Pathogenicity in the Gastric Microenvironment.

Authors:  Jacek Baj; Alicja Forma; Monika Sitarz; Piero Portincasa; Gabriella Garruti; Danuta Krasowska; Ryszard Maciejewski
Journal:  Cells       Date:  2020-12-25       Impact factor: 6.600

6.  A phase I study to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic profiles of ocular GLH8NDE in healthy male adults.

Authors:  Jihyun Jung; Ki Young Huh; Xuanyou Jin; Ahnul Ha; Ki Ho Park; Jun Sang Park; Eunjung Kim; Jaehwi Lee; In-Jin Jang; Howard Lee
Journal:  Clin Transl Sci       Date:  2021-09-15       Impact factor: 4.689

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.